Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
November 13, 2025
Earnings Call Speaker Segments
Operator
operatorGood morning, ladies and gentlemen, and thank you for waiting. The conference is about to start. Once more, we appreciate your patience. Your conference will begin shortly. Hello, and welcome to the conference call covering Palatin's operating results for the first quarter of fiscal year 2026. Right now, every participant is in a listen-only mode. After the formal presentation, there will be a question-and-answer session. Should you need operator assistance at any point during the conference, press *0 on your telephone keypad. Please be aware that this conference call is being recorded. Before we make our remarks, I want to remind everyone that statements Palatin makes that are not historical facts may constitute forward-looking statements. Such statements rest on assumptions that may or may not turn out to be accurate, and actual results could differ materially from those anticipated because of the variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. As you evaluate these forward-looking statements regarding Palatin's prospects, please consider such risks and uncertainties carefully. I would now like to hand the call over to your host, Dr. Carl Spana, President and Chief Executive Officer of Palatin. Please go ahead.
Carl Spana
executiveThanks. Morning, everyone, and glad to have you on Palatin's call for the first quarter of fiscal year 2026. Dr. Carl Spana here — I serve as CEO and President of Palatin. Joining me today is Steve Wills, who holds the roles of Chief Financial Officer and Chief Operating Officer at Palatin. At this point I'll hand things over to Steve; he'll walk through the financial update and touch on a number of corporate matters too. Steve.
Steve Wills
executiveThank you, Carl. Good morning, good afternoon, and good evening, everyone. Turning to the update on our out-licensing programs: in August 2025, we entered into a research collaboration, license, and patent assignment agreement with Boehringer Ingelheim covering the treatment of retinal diseases. Under that deal, we received an upfront payment of €2 million, or approximately $2.3 million, in August of 2025, and in September 2025 we achieved a research milestone of €5.5 million, or approximately $6.5 million. Beyond that, we are eligible to receive up to €12.5 million, or approximately $14.5 million, in additional near-term research milestones, and up to €260 million, or approximately $307 million, in development, regulatory, and commercial milestones, plus tiered royalties on future net sales. On the corporate side, regarding the public offering and NYSE American: on November 12th, 2025, Palatin announced the closing of its upsized $18.2 million underwritten public offering, including the full exercise of the overallotment option. That offering consisted of approximately 2.8 million shares of common stock or pre-funded warrants, together with Series J warrants to purchase up to approximately 2.8 million shares of common stock or pre-funded warrants, and Series K warrants to purchase up to approximately 2.8 million shares of common stock or pre-funded warrants, at a combined public offering price of $6.50 per share of common stock and accompanying Series J and Series K warrants.
Steve Wills
executiveEvery Series J warrant is going to carry an exercise price of $6.50 per share, and it will be exercisable right away. The Series J warrants will expire on whichever comes first: the 18-month anniversary of the original issuance date, or the 31st calendar day after Palatin gets FDA acceptance of an Investigational New Drug for an in-house obesity treatment compound — whether that's a long-acting peptide or an oral small molecule. Each Series K warrant will have an exercise price of $8 and 12.5 cents per share, and it too will be immediately exercisable. The Series K warrants will expire on the five-year anniversary of the original issuance date. But — and this matters — if a holder's Series J warrants haven't been terminated under their terms before the FDA exercise period ends, then that holder's Series K warrants terminate automatically upon the earlier of two things: the 18-month anniversary of the original issuance date of the Series J warrant, or the expiration of the FDA exercise period — and that's before the five-year anniversary of the issuance of the Series K warrant. In plain English, that means if Palatin hits IND acceptance, say in the first half of 2026, which is what we're anticipating, then if the holder doesn't exercise the warrants, the Series J warrant expires and the Series K warrant expires.
Steve Wills
executiveWe expect to get full exercise of the Series J warrants at that performance criteria. Turning to the offering itself, the gross proceeds—before subtracting underwriting discounts, commissions, and offering expenses—are anticipated to come in at roughly $16.9 million. On top of that, Palatin could bring in as much as $18.2 million more from cash exercises of the milestone-related Series J warrants I just mentioned. That said, there's no assurance those warrants will be exercised, and so Palatin would receive any proceeds from such exercise. Palatin plans to apply the net proceeds from the offering toward supporting development of its obesity program, along with working capital and general corporate purposes. As for NYSE American, we're quite pleased with how the offering turned out here, as well as some of the other operating activities, but specifically because the offering closed, Palatin regained compliance with NYSE American continued listing standards. Effective November 12th, yesterday, 2025, Palatin's common stock resumed trading on the NYSE American under the symbol PTN, which was our old symbol back when we were on the NYSE American Exchange. Turning to the financial results for the quarter ended September 30th, 2025, on revenue, for the quarter ended September 30th, 2025, Palatin recognized approximately $8.8 million in collaboration license revenue, versus zero for the comparable quarter last year.
Steve Wills
executiveThe growth in collaboration license revenue is entirely tied to Boehringer Ingelheim — the BI agreement — and it comprised the upfront payment, hitting a research milestone, plus certain reimbursements tied to costs. Turning to operating expenses: total operating expenses came to $4.2 million for the first quarter ended September 30th, 2025, versus $7.8 million in the same quarter a year earlier. That decline was chiefly driven by lower spending on our MCR development programs — the melanocortin receptor system-related development programs. On cash flows: net cash used in operations at Palatin for the quarter ended September 30th, 2025, was $1.6 million, against net cash used in operations of $7 million in the comparable quarter last year. The drop in net cash used in operations stemmed mainly from recognizing license and contract revenue tied to our BI agreement during that quarter. Shifting now to net income and loss: Palatin posted net income of $4.7 million for the quarter ended September 30th, 2025, versus a net loss of $7.8 million in the same quarter the prior year. The rise in net income for the quarter ended September 30th, 2025, was once again primarily attributable to revenue recognized under the BI agreement, and partly to the reduction in operating expenses.
Steve Wills
executiveOn the cash side, as of September 30th, 2025, Palatin's cash and cash equivalents stood at $1.3 million. Yeah, that's on the low side. That compares with $2.6 million in cash and cash equivalents as of June 30th, 2025. That $1.3 million figure for cash and cash equivalents at September 30th, 2025 excludes roughly $6.5 million in milestone payment under our BI agreement for retinal diseases, which came in during October 2025, and, importantly, the net proceeds from our underwritten public offering — again, net proceeds of $16.9 million, with a close on November 12th, 2025. Thanks to the offering's $16.9 million in net proceeds along with projected operating expenses, the going concern provision is no longer in place. Palatin right now anticipates a cash runway past the quarter ending December 31st, 2026. With that, I'll hand things back to Dr. Spana. Carl.
Carl Spana
executiveThank you, Steve. Looking ahead to 2026, our R&D work will center on creating highly selective melanocortin 4 receptor agents to treat different forms of syndromic and genetic obesity, including hypothalamic obesity. The melanocortin receptor system — the melanocortin 4 receptor in particular — plays a critical role in controlling energy balance and food intake, and it is a well-validated target for obesity therapies. Drawing on our technology and deep experience designing and developing melanocortin agonists, we have built a proprietary portfolio of highly selective melanocortin 4 receptor agonists spanning both orally active small molecules and long-acting peptides. Our novel selective melanocortin 4 receptor compounds show reduced activity at the melanocortin 1 receptor, which lowers their potential to cause skin darkening. Absence of activity at the melanocortin 1 receptor, together with once-weekly or oral dosing, represents meaningful improvement over the melanocortin obesity treatments currently approved by the FDA. PL7737 is our orally active small molecule that selectively targets the melanocortin 4 receptor. Across multiple preclinical obesity models, PL7737 has shown substantial decreases in food intake and weight loss. PL7737 is now going through the various activities needed to open an Investigational New Drug application with the FDA, including animal toxicity testing and cGMP manufacturing.
Carl Spana
executivePL7737 remains on schedule to file an IND during the first half of calendar 2026, and the first clinical trials of PL7737 will encompass single ascending as well as multiple ascending studies conducted in healthy, obese, and hypothalamic patients. We anticipate data in the second half of 2026. The melanocortin 4 receptor extended-duration peptides show strong selectivity for the melanocortin 4 receptor and have displayed pharmacokinetic properties consistent with dosing either once a week or once every two-week. IND-enabling studies are expected to begin in the first half of calendar 2026, and first-in-human studies are likewise anticipated in the second half of calendar 2026. Beyond our melanocortin 4 receptor obesity programs, we have several programs built to leverage the part the melanocortin system plays in regulating stress responses and resolution of inflammation. On the basis of this approach, we hold development candidates for multiple ocular indications, inflammatory bowel diseases, and kidney diseases that we expect to out-license. We recently signed a collaboration agreement with Boehringer Ingelheim covering development of candidates to treat various types of retinal diseases, such as diabetic retinopathy or diabetic macular edema. Under this collaboration agreement, we received an upfront payment and are entitled to additional development, clinical, and regulatory milestones, plus royalties on net sales.
Carl Spana
executiveOur deal with Boehringer Ingelheim confirms that going after the melanocortin system holds real promise, and we expect our business development work to center on licensing the rest of our melanocortin receptor system programs. Those take in PL9643, a Phase 3 development candidate for dry eye disease; PL8177, a clinical-stage development candidate for ulcerative colitis; and our preclinical candidates for kidney disease. Other quarter highlights include completing an $18.2 million equity offering, which Steve discussed, and having our stock trade again on the NYSE American under the PTN ticker symbol. Thanks for joining the Palatin first quarter fiscal year 2026 conference call. As a reminder, more information on our programs is available on our website. We will now open the call to questions.
Operator
operatorAbsolutely. At this point, folks, we're going to open things up for questions and answers. Should you have a question or a comment, go ahead and press *1 on your phone now. We do ask that when you ask your question, you lift the handset if you happen to be on speakerphone, so the sound quality stays as good as possible. To repeat, if you've got a question or a comment, just press *1 on your phone. Our first question comes from Scott Henry with AGP. Your line is live.
Scott Henry
analystThank you, and good morning — congratulations on the substantial progress. If I could spend a moment on the pipeline, would you be able to walk us through the ideal target profile for PL7737 in treating HO patients, and also for the long-acting peptides?
Carl Spana
executiveOkay, Scott — thanks for asking. First we'll turn to 7737, an oral compound. In that compound, here's what we want to see: number one, we truly want a meaningful reduction in melanocortin 1 receptor activity, and we know that's been achieved. The other thing we'd like to see, when it comes to treating obesity, is avoiding exposure spikes along with sharp declines in exposure. Essentially, we want compounds with very slow absorption and a very flat pharmacokinetic curve. Such a profile would point to once-a-day dosing and would let us, essentially, hold patients inside the therapeutic window — where the drug is active — for an extended stretch of time. There are no dips; we want that drug staying where it's active for as long as possible, since we know that once patients fall outside that range — as we've seen with other obesity treatments — they begin eating again. You really want to keep them up there. That's essentially what 7737 has achieved. It shows a very long half-life in rat, mouse, and dogs, and we expect the same in humans as well.
Carl Spana
executiveSo because of that, we're able to maintain dosing at a steady state and let these patients remain in that therapeutic window over a prolonged period, which really maximizes efficacy. That's quite similar to what we're aiming to achieve with the long-acting peptides too. Again, they get absorbed, they bind to plasma proteins very quickly, and they show a very flat, long, extended pharmacokinetic profile. Such profiles are ideal when treating obesity patients. We steer clear of spikes — we don't want a rapid spike to a very high Cmax, for instance, since that can produce side effects like GI side effects, and we want to avoid those; you want to keep absorption essentially steady, slow, steady, and flat. Those, I think, really are the ideal parameters, and we observe that for both of our peptides and we observe it for the orally active small molecule. We believe we truly have a very nice profile that will play out very well in terms of both reducing side effects and increasing efficacy.
Scott Henry
analystAlright, thanks Carl. So these are next-gen compounds. I'm aware that hyperpigmentation was one of the concerns. Could you walk us through how these next-generation compounds tackle some of those side effects within that adverse profile?
Carl Spana
executiveOf course. Pigmentation, or hyperpigmentation, results from activity occurring at the melanocortin 1 receptor. We have worked in this area for quite a while, and we managed to create selective agonists targeting the different receptors. Our grasp of the structure-function relationships is strong, and that has enabled us to bring MC1 receptor activity down substantially. We are discussing selectivity of hundreds to thousand-fold for 4 over 1, which should let us either greatly lessen or possibly remove any chance of skin darkening. That is the way we achieved it.
Scott Henry
analystAll right, that's helpful context. One last thing on the HO programs: a major competitor will be in that space against you. How do you view your positioning within that landscape? For example—
Carl Spana
executiveWhen it comes to any drug market, our view is that this will be a market worth multiple billions of dollars, and multiple companies will be able to compete in it. What it ultimately hinges on, I believe, is how good the compounds are that you advance. Regarding their compounds, I won't offer any comment — obviously the first one of theirs that ought to get approved will be a first generation. We're aware it carries MC1 activity and offers once-a-day dosing. They also have additional compounds that sit further back in development. Information on those is limited, and I won't comment on them. What I will say is this: to be a participant in that marketplace, you need the kind of compounds that we have in both our long-acting peptide and our orally active small molecule — namely reduction of MC1, elimination of potential hyperpigmentation, and an efficacy profile and exposure profile that really limits the potential for GI side effects while maximizing the potential for activity. On where we stand, we have a great deal of confidence and are very comfortable with our compounds. We believe their properties are truly excellent for success, and once we get into the clinic, we're going to prove that.
Scott Henry
analystAll right, and thanks — this will be our last question. That BI partnership delivered a meaningful sum of non-dilutive capital. Can you offer any guidance on when we might expect the next collaboration, covering some of the other compounds in the pipeline? Thank you.
Steve Wills
executiveHi Scott, Steve here. We felt really good about how the BI — the Boehringer Ingelheim — collaboration was executed, and about the partnership itself. We had spent a considerable amount of time dating before we signed with BI, and after signing, things have gone wonderfully — they're a truly excellent team to work with. Beyond the initial upfront payment of $2.3 million and the $6.5 million for the milestone achievement, we've said that we expect near-term research and development milestones of roughly $15 million, and the guidance I can offer is that by near-term I mean within the next 12 months. I hope that helps.
Scott Henry
analystAll right, and thanks for the questions.
Steve Wills
executiveThanks, Scott.
Operator
operatorThanks. That brings our Q&A session to a close. At this point I'll turn the conference back over to Dr. Spana for some closing remarks. Go ahead.
Carl Spana
executiveThank you. This has been a truly outstanding quarter for us, especially with the Boehringer Ingelheim collaboration — that took a very long stretch of time to finalize, but we're extremely proud of it and very glad to be partnering with them. We believe they'll be an exceptional partner for our retinal program. Completing the financing with some truly excellent investors, and honestly the dedicated effort put in by Steve and others to get us relisted on the NYSE AMEX and off the pink sheets, was another major achievement. We're genuinely very pleased with where we stand, the opportunity ahead of us, and having the capital to actually execute. We're really looking forward to keeping you all informed about our progress and to getting out there and meeting with various investors between quarters. That said, really the remainder of 2020 — or as we view 2026 from a calendar standpoint — we anticipate a great deal happening with Palatin, and we're genuinely excited here, working hard, and we look forward to keeping you updated. Have a great day, stay safe, enjoy the holidays. Thanks.
Operator
operatorThanks, everybody. That wraps up today's event. You can go ahead and disconnect now, and we hope you have a wonderful day. We appreciate your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.